Developer docs
API playgroundTry for free, no card

Search company profiles

Ectica Technologies

Full company profile

uuid000qyou

Namestring
Ectica Technologies
Legal namestring
Ectica Technologies AG
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Ectica Technologies AG is a Swiss life-science tools company founded in 2015 as a spin-off of ETH Zurich and the University (Hospital) Zurich, headquartered in Bioggio (Canton Ticino) with R&D operations in Zurich. The company develops and commercializes the patented 3DProSeed® platform — a synthetic poly(ethylene glycol)-based hydrogel system engineered with in-depth density gradients at the hydrogel surface that enable cells to penetrate the 3D matrix without encapsulation. The platform is delivered in 96-well imaging-plate format (180-micron glass bottom, ANSI footprint), pre-assembled and hydrated, and is positioned as workflow-compatible with standard high-content screening infrastructure.

The company's commercial portfolio comprises two product families: the 3DProSeed Hydrogel Well Plate (core consumable SKU) and the 3DProSeed StromaLine collection — a catalog of pre-developed, assay-ready ex vivo tumor stromal models spanning cancer-associated fibroblasts from pancreatic, lung, and melanoma tissues, bone-marrow mesenchymal stromal cells, bone-marrow vascular niche co-cultures, and fibrosis-relevant fibroblastic models. Revenue is generated through (i) one-time catalog product sales to pre-clinical CROs and biopharmaceutical companies worldwide, and (ii) contract development and manufacturing services for CDMOs and OEM customers seeking custom hydrogel formulations, bioconjugation reactions, surface coatings, and soft polymeric particles. Go-to-market is sales-led and event-driven, with heavy reliance on conference participation (AACR, EACR, SLAS, Swiss Biotech Days, ELRIG) and free introductory videocalls as the primary technical-consultation funnel.

As a founder-controlled private company with 1–10 employees, Ectica has secured only modest disclosed non-dilutive capital (Horizon 2020 SME Instrument Phase 1 EUR 50,000 plus a Venture Kick award of approximately USD 11,000), relying primarily on grant funding, EU innovation programs, and product revenue rather than institutional venture capital. Named enterprise customers include Merck KGaA, and the company holds granted European patent protection (EPO 3049122) on its core density-gradient technology.

Short descriptiontext

Ectica Technologies AG is a Swiss life-science tools company (spin-off of ETH Zurich and University Hospital Zurich) that develops and sells the patented 3DProSeed® synthetic hydrogel platform — including hydrogel well plates and pre-developed StromaLine tumor stromal models — to pre-clinical CROs and biopharmaceutical companies for 3D cell-based drug discovery.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersZurich, Switzerland
HQ citystring
Zurich
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
3D cell culture, hydrogel research tools, tumor stroma models, drug discovery assays, cancer research products
Industry1 code
PRIMARYIMAEABAK
Specialty Polymers & Resins (Engineered Materials)
NAICS code1 code
  • Resin and Synthetic Rubber Manufacturing32521
SIC code1 code
  • Plastic Materials, Synth Resins & Nonvulcan Elastomers2821
Product category
3D Cell Culture Products
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
13DProSeed Hydrogel Products
TypeOne Time License
Description

Sale of pre-assembled 3DProSeed hydrogel plates and StromaLine pre-developed stromal models. Products include catalog items such as ECT.PS1.001.096 (single pack) and ECT.PS1.010.096 (Pack of 10) for hydrogel plates, and various StromaLine products for specific cancer types. Revenue is generated through direct product sales to research institutions, CROs, and biopharma companies.

ectica-technologies.com
2Contract Development and Manufacturing Services
TypeProfessional Services
Description

Custom hydrogel formulation development and manufacturing services for CDMOs and companies seeking tailored hydrogel solutions. Services include bioconjugation reactions of biocompatible polymers, hydrogel surface coatings, surface patterning, and soft polymeric particle development. Customization available in terms of chemistry, product format, and branding.

ectica-technologies.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
13DProSeed Hydrogel Well Plate catalog products
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Catalog products: ECT.PS1.001.096 (single pack) and ECT.PS1.010.096 (Pack of 10 individually sealed plates). Custom OEM hydrogel solutions available with tailored pricing.

ectica-technologies.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
13DProSeed
Description

Patented synthetic PEG-based hydrogel platform with in-depth density gradients for 3D cell culture in 96-well plates, delivered hydrated and ready for cell seeding

ectica-technologies.com
+1 more record
Core offering1 text field

Ectica Technologies develops and manufactures synthetic poly(ethylene glycol)-based hydrogel products (the 3DProSeed platform) and pre-developed ex vivo tumor stromal models (3DProSeed StromaLine) for 3D cell culture in drug discovery and cancer research. The products are sold as 96-well imaging plates delivered hydrated and ready for cell seeding, targeted at pre-clinical Contract Research Organizations and biopharmaceutical companies. The company also provides contract development and manufacturing of customized OEM hydrogel formulations, coatings and bioconjugation services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • High-content screening-compatible stromal models enable new discoveries in oncology and fibrosis with minimal adaptation efforts
+1 more record
Product overview1 text field

Ectica Technologies offers a portfolio centered on the 3DProSeed technology platform, which combines patented synthetic poly(ethylene glycol)-based hydrogels with 96-well imaging plate formats for 3D cell-based assays. The core 3DProSeed Hydrogel Well Plate provides the foundational technology featuring an in-depth density gradient that enables cell penetration without encapsulation. The 3DProSeed StromaLine collection extends the platform with pre-developed, assay-ready stromal models including cancer-associated fibroblasts (CAFs) from pancreatic, lung, and melanoma tissues, bone marrow mesenchymal stromal cells, bone marrow vascular niche co-cultures, and human fibroblastic cultures for fibrosis research. All StromaLine products come with optimized medium, reagents, and the compatible hydrogel plate as a complete system. The company also provides contract development and manufacturing services for customized hydrogel formulations.

Product and service9 records
13DProSeed Hydrogel Well Plate
Category3D cell culture consumable / hydrogel plate
Description

96-well black glass-bottom imaging plate containing pre-assembled synthetic poly(ethylene glycol)-based hydrogels delivered hydrated and ready for cell seeding, with patented in-depth density gradients enabling cells to penetrate into the 3D matrix without encapsulation; standard ANSI footprint for high-content screening and microscopy workflows, used by CROs and biopharma researchers running 3D cell-based assays.

23DProSeed StromaLine Collection
Category3D tumor stroma model product line
Description

Family of pre-developed ex vivo tumor stromal models in 3DProSeed synthetic hydrogels, supplied as assay-ready 96-well plates with optimized medium and reagents for tumor-stroma interaction studies and drug screening.

33DProSeed StromaLine Pancreatic CAFs
Category3D tumor stroma model / pancreatic CAFs
Description

Pre-developed human stromal model with patient-derived pancreatic cancer-associated fibroblasts in synthetic 3D hydrogels, sold as a 96-well imaging plate for tumor-stroma interaction and anti-cancer drug screening studies.

43DProSeed StromaLine Lung CAFs
Category3D tumor stroma model / lung CAFs
Description

Pre-developed human stromal model with patient-derived lung cancer-associated fibroblasts (CAFs) from invasive squamous cell carcinomas, supplied in synthetic 3D hydrogels in 96-well imaging plate format (catalog ECT.STRL.LUNCAF.096) for tumor-stroma interaction studies.

53DProSeed StromaLine Melanoma CAFs
Category3D tumor stroma model / melanoma CAFs
Description

Pre-developed human stromal model with patient-derived malignant melanoma cancer-associated fibroblasts in synthetic 3D hydrogels, supplied in 96-well imaging plate format (catalog ECT.STRL.MECAF.096) for studying the stromal component of the melanoma tumor microenvironment.

63DProSeed StromaLine Bone-Marrow MSC
Category3D stromal model / bone marrow MSC
Description

3D culture platform for multipotent stromal cells from normal adult human bone marrow on synthetic PEG-based hydrogel that supports deposition and assembly of native extracellular matrix resembling bone marrow stroma, supplied in 96-well format (catalog ECT.STRL.BMMSC.096).

73DProSeed StromaLine Bone-Marrow Vascular Niche
Category3D stromal model / vascular niche co-culture
Description

Pre-developed co-culture system of human bone marrow mesenchymal stromal cells and endothelial cells in synthetic 3D hydrogels modelling the (peri)vascular niche for angiogenesis and vasculogenesis studies, supplied in 96-well format (catalog ECT.STRL.BMVAS.096).

83DProSeed StromaLine Human Fibroblastic Cultures
Category3D fibrosis model / fibroblastic culture
Description

3D organotypic models using primary cardiac and pulmonary fibroblasts and primary human hepatic stellate cells in proprietary precast synthetic hydrogels, used to screen pro- and anti-fibrotic molecules via microscopy and biochemical biomarker analysis.

9Hydrogel Development and Manufacturing Services
CategoryCustom hydrogel CDMO / OEM services
Description

Contract development and OEM manufacturing services for customized hydrogel formulations, including bioconjugation of activated poly(ethylene glycols), hydrogel surface coatings and surface patterning, and soft polymeric particle development, with customization in chemistry, product format and branding for CDMOs and OEM partners.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-13
Description

Strategic alliance announced December 2023 to strengthen Nordic Bioscience's translational in vitro model offering. Nordic Bioscience offers specialized 3DPROFIB assays for fibrosis using their large biomarker library measuring extracellular matrix formation and degradation, combined with Ectica's hydrogel cell-based platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-10-18
Description

Research collaboration to pursue novel platform creation on cancer metastasis. Mestastop has proprietary technologies around metastasis drug discovery and early predictive diagnostics. Ectica contributes hydrogel-based co-culture platforms for tumor-stroma interaction studies. Collaboration aims to share know-how in genetic engineering and functional phenotypic cell-based assays for metastasis research.

3SCREEN Holdings Co. Ltd
Strategic tierCoreTypeTechnology or Integration
Description

Joint exhibition partnership at multiple conferences including AACR 2022 and PREDiCT 3D Tissue Models Summit. Collaboration on label-free 3D tomographic imaging of organotypic cultures developed in 3DProSeed hydrogel plate. SCREEN provides infrared laser-based optical coherence tomography technology for non-invasive imaging of tumoroids and organoids.

ectica-technologies.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

CTI/KTI project collaboration with Dr. Tackenberg at University of Zurich, Dr. Ehrbar at University Hospital Zurich, and Dr. Schmutz at EMPA. Project focuses on further developing applications and manufacturing aspects of 3DProSeed technology.

5Merck Accelerator
Strategic tierMinorTypeGTM or Marketing Partner
Description

Selected participant in Merck Accelerator program, providing opportunity to internationalize business and reach global market. Part of Merck's innovation ecosystem supporting startups.

ectica-technologies.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Sponsors and supporters of Ectica Technologies, enabling participation in international business development activities such as BioEurope conferences.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

InSphero provides 3D organoid and spheroid disease models for drug discovery and toxicology. Like Ectica, it sells defined, assay-ready 3D cell-culture tools to pharma/CROs for oncology and metabolic disease research.

TypeDirect peer
Description

MIMETAS develops organ-on-chip and 3D tissue models for disease modeling and drug screening, including tumor-stroma interaction platforms. Directly comparable as a specialty 3D tissue-model tools vendor targeting the same biopharma buyer.

TypeDirect peer
Description

Cellink/BICO develops bioinks, hydrogels, and bioprinting platforms for 3D cell culture, with comparable PEG/hydrogel chemistries positioned for cancer research and tissue engineering. Overlaps in hydrogel chemistry, lab automation, and life-science-tools GTM.

4QNano / QGel Bio
TypeDirect peer
Description

QGel develops synthetic, animal-free PEG-based hydrogels for organoid and 3D cell culture in drug discovery. Most direct technical competitor given shared PEG hydrogel chemistry and oncology drug-discovery customer base.

TypeEmerging player
Description

Lena Biosciences offers 3D cell culture and tissue-engineering hydrogel platforms for cancer and drug-discovery research. Comparable as a smaller specialty hydrogel-tools peer with similar oncology/cancer-research focus.

6Corning Life Sciences
TypeBroad incumbent
Description

Corning Matrigel and Corning spheroid plates dominate the 3D cell-culture and organoid tools market and compete with Ectica's hydrogels in the same pharma/CRO applications. Broad incumbent in cell-culture plastics and matrices.

TypeBroad incumbent
Description

Thermo Fisher sells Gibco/Geltrex 3D matrices and a broad cell-culture portfolio directly competing with Ectica in tumor-stroma and high-content screening applications. The largest incumbent in life-science research tools.

TypeEmerging player
Description

Organovo develops 3D bioprinted human tissue models for drug discovery and disease research, with a focus on oncology and fibrosis. Comparable as a tissue-modeling platform targeting pharma screening applications.

TypeEmerging player
Description

Emulate develops organ-on-chip platforms (Liver-Chip, etc.) for preclinical drug testing. Adjacent to Ectica as an emerging alternative 3D in-vitro model platform for pharma R&D.

TypeBroad incumbent
Description

Lonza provides primary cells, 3D cell-culture reagents, and custom hydrogel/media services for pharma R&D. Competes in the same cell-culture tools space with a much broader portfolio and global manufacturing footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ectica Technologies

3D Cell Culture Productsectica-technologies.com

Ectica Technologies AG is a Swiss life-science tools company (spin-off of ETH Zurich and University Hospital Zurich) that develops and sells the patented 3DProSeed® synthetic hydrogel platform — including hydrogel well plates and pre-developed StromaLine tumor stromal models — to pre-clinical CROs and biopharmaceutical companies for 3D cell-based drug discovery.

What Ectica Technologies does

Ectica Technologies AG is a Swiss life-science tools company founded in 2015 as a spin-off of ETH Zurich and the University (Hospital) Zurich, headquartered in Bioggio (Canton Ticino) with R&D operations in Zurich. The company develops and commercializes the patented 3DProSeed® platform — a synthetic poly(ethylene glycol)-based hydrogel system engineered with in-depth density gradients at the hydrogel surface that enable cells to penetrate the 3D matrix without encapsulation. The platform is delivered in 96-well imaging-plate format (180-micron glass bottom, ANSI footprint), pre-assembled and hydrated, and is positioned as workflow-compatible with standard high-content screening infrastructure.

The company's commercial portfolio comprises two product families: the 3DProSeed Hydrogel Well Plate (core consumable SKU) and the 3DProSeed StromaLine collection — a catalog of pre-developed, assay-ready ex vivo tumor stromal models spanning cancer-associated fibroblasts from pancreatic, lung, and melanoma tissues, bone-marrow mesenchymal stromal cells, bone-marrow vascular niche co-cultures, and fibrosis-relevant fibroblastic models. Revenue is generated through (i) one-time catalog product sales to pre-clinical CROs and biopharmaceutical companies worldwide, and (ii) contract development and manufacturing services for CDMOs and OEM customers seeking custom hydrogel formulations, bioconjugation reactions, surface coatings, and soft polymeric particles. Go-to-market is sales-led and event-driven, with heavy reliance on conference participation (AACR, EACR, SLAS, Swiss Biotech Days, ELRIG) and free introductory videocalls as the primary technical-consultation funnel.

As a founder-controlled private company with 1–10 employees, Ectica has secured only modest disclosed non-dilutive capital (Horizon 2020 SME Instrument Phase 1 EUR 50,000 plus a Venture Kick award of approximately USD 11,000), relying primarily on grant funding, EU innovation programs, and product revenue rather than institutional venture capital. Named enterprise customers include Merck KGaA, and the company holds granted European patent protection (EPO 3049122) on its core density-gradient technology.

Ectica Technologies firmographics

Firmographics
Name
Ectica Technologies
Legal name
Ectica Technologies AG
Website
https://ectica-technologies.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Ectica Technologies AG is a Swiss life-science tools company (spin-off of ETH Zurich and University Hospital Zurich) that develops and sells the patented 3DProSeed® synthetic hydrogel platform — including hydrogel well plates and pre-developed StromaLine tumor stromal models — to pre-clinical CROs and biopharmaceutical companies for 3D cell-based drug discovery.
Ownership category
akta.pro rank

Ectica Technologies industry classification

Industry
Product category
3D Cell Culture Products
NAICS
Resin and Synthetic Rubber Manufacturing (32521)
SIC
Plastic Materials, Synth Resins & Nonvulcan Elastomers (2821)
akta.pro industry
PRIMARYIMAEABAK
Specialty Polymers & Resins (Engineered Materials)

Keywords

  • 3D cell culture
  • Hydrogel research tools
  • Tumor stroma models
  • Drug discovery assays
  • Cancer research products

Where Ectica Technologies is headquartered

Location

Headquarters

HQ city
Zurich
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Ectica Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. 3DProSeed Hydrogel Products: Sale of pre-assembled 3DProSeed hydrogel plates and StromaLine pre-developed stromal models. Products include catalog items such as ECT.PS1.001.096 (single pack) and ECT.PS1.010.096 (Pack of 10) for hydrogel plates, and various StromaLine products for specific cancer types. Revenue is generated through direct product sales to research institutions, CROs, and biopharma companies.
  2. Contract Development and Manufacturing Services: Custom hydrogel formulation development and manufacturing services for CDMOs and companies seeking tailored hydrogel solutions. Services include bioconjugation reactions of biocompatible polymers, hydrogel surface coatings, surface patterning, and soft polymeric particle development. Customization available in terms of chemistry, product format, and branding.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-go3DProSeed Hydrogel Well Plate catalog products

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Ectica Technologies product offering

Product offering

Core offering

Ectica Technologies develops and manufactures synthetic poly(ethylene glycol)-based hydrogel products (the 3DProSeed platform) and pre-developed ex vivo tumor stromal models (3DProSeed StromaLine) for 3D cell culture in drug discovery and cancer research. The products are sold as 96-well imaging plates delivered hydrated and ready for cell seeding, targeted at pre-clinical Contract Research Organizations and biopharmaceutical companies. The company also provides contract development and manufacturing of customized OEM hydrogel formulations, coatings and bioconjugation services.

Product overview

Ectica Technologies offers a portfolio centered on the 3DProSeed technology platform, which combines patented synthetic poly(ethylene glycol)-based hydrogels with 96-well imaging plate formats for 3D cell-based assays. The core 3DProSeed Hydrogel Well Plate provides the foundational technology featuring an in-depth density gradient that enables cell penetration without encapsulation. The 3DProSeed StromaLine collection extends the platform with pre-developed, assay-ready stromal models including cancer-associated fibroblasts (CAFs) from pancreatic, lung, and melanoma tissues, bone marrow mesenchymal stromal cells, bone marrow vascular niche co-cultures, and human fibroblastic cultures for fibrosis research. All StromaLine products come with optimized medium, reagents, and the compatible hydrogel plate as a complete system. The company also provides contract development and manufacturing services for customized hydrogel formulations.

Differentiator

Problem solved

Functional benefit

Brands

  • 3DProSeed: Patented synthetic PEG-based hydrogel platform with in-depth density gradients for 3D cell culture in 96-well plates, delivered hydrated and ready for cell seeding
  • 3DProSeed StromaLine

Products and services

  • 3DProSeed Hydrogel Well Plate 96-well black glass-bottom imaging plate containing pre-assembled synthetic poly(ethylene glycol)-based hydrogels delivered hydrated and ready for cell seeding, with patented in-depth density gradients enabling cells to penetrate into the 3D matrix without encapsulation; standard ANSI footprint for high-content screening and microscopy workflows, used by CROs and biopharma researchers running 3D cell-based assays.
  • 3DProSeed StromaLine Collection Family of pre-developed ex vivo tumor stromal models in 3DProSeed synthetic hydrogels, supplied as assay-ready 96-well plates with optimized medium and reagents for tumor-stroma interaction studies and drug screening.
  • 3DProSeed StromaLine Pancreatic CAFs Pre-developed human stromal model with patient-derived pancreatic cancer-associated fibroblasts in synthetic 3D hydrogels, sold as a 96-well imaging plate for tumor-stroma interaction and anti-cancer drug screening studies.
  • 3DProSeed StromaLine Lung CAFs Pre-developed human stromal model with patient-derived lung cancer-associated fibroblasts (CAFs) from invasive squamous cell carcinomas, supplied in synthetic 3D hydrogels in 96-well imaging plate format (catalog ECT.STRL.LUNCAF.096) for tumor-stroma interaction studies.
  • 3DProSeed StromaLine Melanoma CAFs Pre-developed human stromal model with patient-derived malignant melanoma cancer-associated fibroblasts in synthetic 3D hydrogels, supplied in 96-well imaging plate format (catalog ECT.STRL.MECAF.096) for studying the stromal component of the melanoma tumor microenvironment.
  • 3DProSeed StromaLine Bone-Marrow MSC 3D culture platform for multipotent stromal cells from normal adult human bone marrow on synthetic PEG-based hydrogel that supports deposition and assembly of native extracellular matrix resembling bone marrow stroma, supplied in 96-well format (catalog ECT.STRL.BMMSC.096).
  • 3DProSeed StromaLine Bone-Marrow Vascular Niche Pre-developed co-culture system of human bone marrow mesenchymal stromal cells and endothelial cells in synthetic 3D hydrogels modelling the (peri)vascular niche for angiogenesis and vasculogenesis studies, supplied in 96-well format (catalog ECT.STRL.BMVAS.096).
  • 3DProSeed StromaLine Human Fibroblastic Cultures 3D organotypic models using primary cardiac and pulmonary fibroblasts and primary human hepatic stellate cells in proprietary precast synthetic hydrogels, used to screen pro- and anti-fibrotic molecules via microscopy and biochemical biomarker analysis.
  • Hydrogel Development and Manufacturing Services Contract development and OEM manufacturing services for customized hydrogel formulations, including bioconjugation of activated poly(ethylene glycols), hydrogel surface coatings and surface patterning, and soft polymeric particle development, with customization in chemistry, product format and branding for CDMOs and OEM partners.

Quantifiable outcome

  • High-content screening-compatible stromal models enable new discoveries in oncology and fibrosis with minimal adaptation efforts
  • +1 more outcomes

Companies that use Ectica Technologies

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Ectica Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Ectica Technologies partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Nordic BiosciencecoreStrategic or Co-development Partner · 13 December 2023Strategic alliance announced December 2023 to strengthen Nordic Bioscience's translational in vitro model offering. Nordic Bioscience offers specialized 3DPROFIB assays for fibrosis using their large biomarker library measuring extracellular matrix formation and degradation, combined with Ectica's hydrogel cell-based platform.
  • Mestastop SolutionscoreStrategic or Co-development Partner · 18 October 2022Research collaboration to pursue novel platform creation on cancer metastasis. Mestastop has proprietary technologies around metastasis drug discovery and early predictive diagnostics. Ectica contributes hydrogel-based co-culture platforms for tumor-stroma interaction studies. Collaboration aims to share know-how in genetic engineering and functional phenotypic cell-based assays for metastasis research.
  • SCREEN Holdings Co. LtdcoreTechnology or IntegrationJoint exhibition partnership at multiple conferences including AACR 2022 and PREDiCT 3D Tissue Models Summit. Collaboration on label-free 3D tomographic imaging of organotypic cultures developed in 3DProSeed hydrogel plate. SCREEN provides infrared laser-based optical coherence tomography technology for non-invasive imaging of tumoroids and organoids.
  • University of Zurich, University Hospital Zurich, and EMPAminorStrategic or Co-development PartnerCTI/KTI project collaboration with Dr. Tackenberg at University of Zurich, Dr. Ehrbar at University Hospital Zurich, and Dr. Schmutz at EMPA. Project focuses on further developing applications and manufacturing aspects of 3DProSeed technology.
  • Merck AcceleratorminorGTM or Marketing PartnerSelected participant in Merck Accelerator program, providing opportunity to internationalize business and reach global market. Part of Merck's innovation ecosystem supporting startups.
  • InnoSuisse and Swiss Global EnterpriseminorGTM or Marketing PartnerSponsors and supporters of Ectica Technologies, enabling participation in international business development activities such as BioEurope conferences.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Ectica Technologies competitors and assessment

Company assessment

Direct peers

  • InSphero: InSphero provides 3D organoid and spheroid disease models for drug discovery and toxicology. Like Ectica, it sells defined, assay-ready 3D cell-culture tools to pharma/CROs for oncology and metabolic disease research.
  • MIMETAS: MIMETAS develops organ-on-chip and 3D tissue models for disease modeling and drug screening, including tumor-stroma interaction platforms. Directly comparable as a specialty 3D tissue-model tools vendor targeting the same biopharma buyer.
  • Cellink (BICO): Cellink/BICO develops bioinks, hydrogels, and bioprinting platforms for 3D cell culture, with comparable PEG/hydrogel chemistries positioned for cancer research and tissue engineering. Overlaps in hydrogel chemistry, lab automation, and life-science-tools GTM.
  • QNano / QGel Bio: QGel develops synthetic, animal-free PEG-based hydrogels for organoid and 3D cell culture in drug discovery. Most direct technical competitor given shared PEG hydrogel chemistry and oncology drug-discovery customer base.

Emerging players

  • Lena Biosciences: Lena Biosciences offers 3D cell culture and tissue-engineering hydrogel platforms for cancer and drug-discovery research. Comparable as a smaller specialty hydrogel-tools peer with similar oncology/cancer-research focus.
  • Organovo: Organovo develops 3D bioprinted human tissue models for drug discovery and disease research, with a focus on oncology and fibrosis. Comparable as a tissue-modeling platform targeting pharma screening applications.
  • Emulate: Emulate develops organ-on-chip platforms (Liver-Chip, etc.) for preclinical drug testing. Adjacent to Ectica as an emerging alternative 3D in-vitro model platform for pharma R&D.

Broad incumbents

  • Corning Life Sciences: Corning Matrigel and Corning spheroid plates dominate the 3D cell-culture and organoid tools market and compete with Ectica's hydrogels in the same pharma/CRO applications. Broad incumbent in cell-culture plastics and matrices.
  • Thermo Fisher Scientific: Thermo Fisher sells Gibco/Geltrex 3D matrices and a broad cell-culture portfolio directly competing with Ectica in tumor-stroma and high-content screening applications. The largest incumbent in life-science research tools.
  • Lonza Bioscience: Lonza provides primary cells, 3D cell-culture reagents, and custom hydrogel/media services for pharma R&D. Competes in the same cell-culture tools space with a much broader portfolio and global manufacturing footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Ectica Technologies social profiles

Digital presence

Ectica Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ectica Technologies leadership team

Management profile

Number of profiles

Profiles2 records

Ectica Technologies funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ectica Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ectica Technologies

What does Ectica Technologies do?

Ectica Technologies develops and manufactures synthetic poly(ethylene glycol)-based hydrogel products (the 3DProSeed platform) and pre-developed ex vivo tumor stromal models (3DProSeed StromaLine) for 3D cell culture in drug discovery and cancer research. The products are sold as 96-well imaging plates delivered hydrated and ready for cell seeding, targeted at pre-clinical Contract Research Organizations and biopharmaceutical companies. The company also provides contract development and manufacturing of customized OEM hydrogel formulations, coatings and bioconjugation services.

Is Ectica Technologies a public or private company?

Ectica Technologies is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Ectica Technologies founded?

Ectica Technologies was founded in 2015. It employs 1 to 10 people.

Where is Ectica Technologies based?

Ectica Technologies is headquartered in Zurich, Switzerland, in the Europe region.

How does Ectica Technologies make money?

Two revenue lines are on record. 3DProSeed Hydrogel Products are the primary driver. The others are contract Development and Manufacturing Services.

Who are Ectica Technologies's main competitors?

Direct peers on record are InSphero, MIMETAS, Cellink (BICO) and QNano / QGel Bio. Emerging players are Lena Biosciences, Organovo and Emulate. Broad incumbents are Corning Life Sciences, Thermo Fisher Scientific and Lonza Bioscience.

Does Ectica Technologies have an API?

No public API is recorded for Ectica Technologies.

What industry is Ectica Technologies in?

Ectica Technologies's product category is 3D Cell Culture Products. Its primary akta.pro industry code is IMAEABAK, Specialty Polymers & Resins (Engineered Materials). Its NAICS code is 32521 and its SIC code is 2821.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals